Successful silencing of plasminogen activator inhibitor-1 in human vascular endothelial cells using small interfering RNA

Summary Clinical as well as experimental evidence suggests that vascular overexpression of plasminogen activator inhibitor (PAI)-1, the primary physiological inhibitor of both urokinase and tissuetype plasminogen activator, may be involved in the pathophysiology of atherosclerosis and cardiovascular disease. We investigated the feasibility, efficacy and functional effects of PAI-1 gene silencing in human vascular endothelial cells using small interfering RNA. Double-stranded 21 bp-RNA molecules targeted at sequences within the human PAI-1 gene were constructed. Successful siRNA transfection of HUVEC was confirmed using fluorescence microscopy and flow cytometry. One of five candidate siRNA sequences reduced PAI-1 mRNA and protein in a concentrationand time-dependent manner. Suppression of PAI-1 mRNA was detected up to 72 hours after transfection. Moreover, siRNA treatment reduced the activity of PAI-1 released from HUVEC, and prevented the oxLDL- or LPS-induced upregulation of PAI-1 secretion. Importantly, siRNA treatment did not affect the expression of other endothelial-cell markers. Moreover, downregulation of PAI-1 significantly enhanced the ability of endothelial cells to adhere to vitronectin, and this effect could be reversed upon addition of recombinant PAI-1. SiRNAmediated reduction of PAI-1 expression may be a promising strategy for dissecting the effects of PAI-1 on vascular homeostasis.

[1]  D. Chang,et al.  The gene-silencing efficiency of siRNA is strongly dependent on the local structure of mRNA at the targeted region. , 2004, Biochemical and biophysical research communications.

[2]  Thomas Tuschl,et al.  siRNAs: applications in functional genomics and potential as therapeutics , 2004, Nature Reviews Drug Discovery.

[3]  A. Reynolds,et al.  Rational siRNA design for RNA interference , 2004, Nature Biotechnology.

[4]  S. Konstantinides,et al.  PAI‐1 and vasculopathy: the debate continues , 2004, Journal of thrombosis and haemostasis : JTH.

[5]  I. Iakovidis,et al.  The road ahead. , 2004, Studies in health technology and informatics.

[6]  Emmanuelle M Mounier,et al.  Enhanced Thrombosis in Atherosclerosis-Prone Mice Is Associated With Increased Arterial Expression of Plasminogen Activator Inhibitor-1 , 2003, Arteriosclerosis, thrombosis, and vascular biology.

[7]  Robert H. Silverman,et al.  Activation of the interferon system by short-interfering RNAs , 2003, Nature Cell Biology.

[8]  E. Vicaut,et al.  Acute Release of Plasminogen Activator Inhibitor-1 in ST-Segment Elevation Myocardial Infarction Predicts Mortality , 2003, Circulation.

[9]  S. Yusuf,et al.  Relationship of Metabolic Syndrome and Fibrinolytic Dysfunction to Cardiovascular Disease , 2003, Circulation.

[10]  Thomas Tuschl,et al.  Sequence, chemical, and structural variation of small interfering RNAs and short hairpin RNAs and the effect on mammalian gene silencing. , 2003, Antisense & nucleic acid drug development.

[11]  Jean-Philippe Richard,et al.  Cellular uptake and intracellular fate of antisense oligonucleotides. , 2003, Current opinion in molecular therapeutics.

[12]  R. Czekay,et al.  Plasminogen activator inhibitor-1 detaches cells from extracellular matrices by inactivating integrins , 2003, The Journal of cell biology.

[13]  C. F. Bennett,et al.  Efficient Reduction of Target RNAs by Small Interfering RNA and RNase H-dependent Antisense Agents , 2003, The Journal of Biological Chemistry.

[14]  P. Opolon,et al.  Comparison of antisense oligonucleotides and siRNAs in cell culture and in vivo. , 2002, Biochemical and biophysical research communications.

[15]  T. Tuschl,et al.  Small interfering RNAs: a revolutionary tool for the analysis of gene function and gene therapy. , 2002, Molecular interventions.

[16]  A. Luttun,et al.  Lack of Plasminogen Activator Inhibitor-1 Promotes Growth and Abnormal Matrix Remodeling of Advanced Atherosclerotic Plaques in Apolipoprotein E–Deficient Mice , 2002, Arteriosclerosis, thrombosis, and vascular biology.

[17]  R. Czekay,et al.  Plasminogen activator inhibitor‐1 regulates cell adhesion by binding to the somatomedin B domain of vitronectin , 2001, Journal of cellular physiology.

[18]  D. Loskutoff,et al.  Disruption of the plasminogen activator inhibitor‐1 gene reduces the adiposity and improves the metabolic profile of genetically obese and diabetic ob/ob mice , 2001, FASEB journal : official publication of the Federation of American Societies for Experimental Biology.

[19]  T. Tuschl,et al.  Duplexes of 21-nucleotide RNAs mediate RNA interference in cultured mammalian cells , 2001, Nature.

[20]  P. Libby,et al.  Inflammation and thrombosis: the clot thickens. , 2001, Circulation.

[21]  Christopher K. Glass,et al.  Atherosclerosis The Road Ahead , 2001, Cell.

[22]  D. Loskutoff,et al.  Plasminogen Activator Inhibitor-1 and Its Cofactor Vitronectin Stabilize Arterial Thrombi After Vascular Injury in Mice , 2001, Circulation.

[23]  R. Westrick,et al.  Plasminogen activator inhibitor-1 deficiency protects against atherosclerosis progression in the mouse carotid artery. , 2000, Blood.

[24]  R. Plasterk,et al.  The silence of the genes. , 2000, Current opinion in genetics & development.

[25]  R. Benza,et al.  Hypertriglyceridemic VLDL downregulates tissue plasminogen activator gene transcription through cis-repressive region(s) in the tissue plasminogen activator promoter in cultured human endothelial cells. , 2000, Arteriosclerosis, thrombosis, and vascular biology.

[26]  E. Nabel,et al.  Atherosclerosis progression in LDL receptor-deficient and apolipoprotein E-deficient mice is independent of genetic alterations in plasminogen activator inhibitor-1. , 2000, Arteriosclerosis, thrombosis, and vascular biology.

[27]  A. Hamsten,et al.  Oxidized LDL and lysophosphatidylcholine stimulate plasminogen activator inhibitor-1 expression in vascular smooth muscle cells. , 1999, Arteriosclerosis, thrombosis, and vascular biology.

[28]  A. Hamsten,et al.  Effects of native, triglyceride-enriched, and oxidatively modified LDL on plasminogen activator inhibitor-1 expression in human endothelial cells. , 1999, Arteriosclerosis, thrombosis, and vascular biology.

[29]  M. Skobe,et al.  Absence of host plasminogen activator inhibitor 1 prevents cancer invasion and vascularization , 1998, Nature Medicine.

[30]  A. Fire,et al.  Potent and specific genetic interference by double-stranded RNA in Caenorhabditis elegans , 1998, Nature.

[31]  W. Stec,et al.  Phosphorothioate Oligodeoxyribonucleotides Antisense to PAI-1 mRNA Increase Fibrinolysis and Modify Experimental Thrombosis in Rats , 1998, Thrombosis and Haemostasis.

[32]  P. Carmeliet,et al.  Inhibitory role of plasminogen activator inhibitor-1 in arterial wound healing and neointima formation: a gene targeting and gene transfer study in mice. , 1997, Circulation.

[33]  Y. Wei,et al.  Plasmin and plasminogen activator inhibitor type 1 promote cellular motility by regulating the interaction between the urokinase receptor and vitronectin. , 1997, The Journal of clinical investigation.

[34]  Takayuki Asahara,et al.  Isolation of Putative Progenitor Endothelial Cells for Angiogenesis , 1997, Science.

[35]  K. Preissner,et al.  The urokinase receptor is a major vitronectin-binding protein on endothelial cells. , 1996, Experimental cell research.

[36]  D. Lawrence,et al.  The serpin PAI-1 inhibits cell migration by blocking integrin alpha V beta 3 binding to vitronectin. , 1996, Nature.

[37]  W. Stec,et al.  Inhibition by modified oligodeoxynucleotides of the expression of type-1 plasminogen activator inhibitor in human endothelial cells. , 1995, European journal of biochemistry.

[38]  B. Sobel,et al.  Inhibition of type-1 plasminogen activator inhibitor production by antisense oligonucleotides in human vascular endothelial and smooth muscle cells. , 1994, The Journal of biological chemistry.

[39]  B. Binder,et al.  The somatomedin B domain of vitronectin. Structural requirements for the binding and stabilization of active type 1 plasminogen activator inhibitor. , 1994, The Journal of biological chemistry.

[40]  D. Loskutoff,et al.  Increased type 1 plasminogen activator inhibitor gene expression in atherosclerotic human arteries. , 1992, Proceedings of the National Academy of Sciences of the United States of America.

[41]  T. Podor,et al.  Regulation of type 1 plasminogen activator inhibitor gene expression in cultured bovine aortic endothelial cells. Induction by transforming growth factor-beta, lipopolysaccharide, and tumor necrosis factor-alpha. , 1989, The Journal of biological chemistry.

[42]  R. Lebo,et al.  cDNA cloning of human plasminogen activator-inhibitor from endothelial cells. , 1986, The Journal of clinical investigation.